HVDs/HVDPs: tricky business! [RSABE / ABEL]

posted by drsinghs – India, 2012-05-09 14:33 (5146 d 12:48 ago) – Posting: # 8542
Views: 10,031

Dear HS and Dr. Dan,

My query is similar to the ongoing discussion.

Below situation may not be practically feasible but still I am asking this to gain some knowledge. Irrespective of regulatory requirements, cost and other issues; I request valuable opinion from both of you on following.

This is regarding a HVDP. If I check same batch of test and reference by both 2 way crossover and replicate design, what kind of differences in results can I expect?

To be more precise I will share a hypothetical case - if 2 waycrossver study is already completed and observed T/R ratio is 115 for Cmax and 125 for AUCt with > 30% intraCV for Cmax and > 45% for AUCt, Can I expect successful results if I go for replicate design?

Thanks & regards,
drsinghs

Complete thread:

UA Flag
Activity
 Admin contact
23,653 posts in 4,991 threads, 1,570 registered users;
144 visitors (0 registered, 144 guests [including 60 identified bots]).
Forum time: 03:22 CEST (Europe/Vienna)

Outside his own ever-narrowing field of specialization,
a scientist is a layman.
What members of an academy of science have in common
is a certain form of semiparasitic living.    Erwin Chargaff

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5